Sandoz wins FDA approval for first two biosimilars for Amgen’s blockbuster bone drug

Sandoz said Tuesday that the FDA signed off on two of its biosimilars to Amgen’s bone drug denosumab. But as with other high-profile biosimilar approvals, it’s unclear when either of the two new products might launch and how low prices may fall.

The approvals are the first sign that Amgen’s…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks